433 related articles for article (PubMed ID: 23497761)
1. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
3. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects.
Nave R; Schmitt H; Popper L
Drug Deliv; 2013; 20(5):216-23. PubMed ID: 23650968
[TBL] [Abstract][Full Text] [Related]
4. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
6. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
J Clin Pharmacol; 2007 Mar; 47(3):343-50. PubMed ID: 17322146
[TBL] [Abstract][Full Text] [Related]
7. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study.
Vasisht N; Gever LN; Tagarro I; Finn AL
Clin Drug Investig; 2009; 29(10):647-54. PubMed ID: 19715381
[TBL] [Abstract][Full Text] [Related]
8. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Plock N; Facius A; Hartmann L; Baumann S; Nave R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Feb; 48(2):138-45. PubMed ID: 20137766
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers.
Fisher A; Watling M; Smith A; Knight A
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):860-7. PubMed ID: 21084042
[TBL] [Abstract][Full Text] [Related]
12. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate.
Lee M; Kern SE; Kisicki JC; Egan TD
J Pain Symptom Manage; 2003 Aug; 26(2):743-7. PubMed ID: 12906959
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers.
Lim CB; Schug SA; Sunderland VB; Paech MJ; Liu Y
Anesth Analg; 2012 Sep; 115(3):554-9. PubMed ID: 22584544
[TBL] [Abstract][Full Text] [Related]
16. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
17. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
